Screener
Avalo Therapeutics AVTX Gross margin
Gross margin at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Avalo Therapeutics’s 10-Q, filed November 6, 2025. Open the filing →
- Filed
- Nov 6, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001534120-25-000018
FAQ
- What is Avalo Therapeutics's gross margin?
- Avalo Therapeutics (AVTX) reported gross margin of 182% in Q3 2024.
- How has Avalo Therapeutics's gross margin changed year-over-year?
- Avalo Therapeutics's gross margin increased by 3201.5% year-over-year, from 5.5% to 182%.
- What is the long-term trend for Avalo Therapeutics's gross margin?
- Over 3 years (2020 to 2023), Avalo Therapeutics's gross margin has grown at a -29.7% compound annual growth rate (CAGR), from 95.5% to 33.2%.
- What does gross margin mean?
- Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.
Ask your AI about Avalo Therapeutics's gross margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude